FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 10, 2010, Pages 1992-1993

  Dalus, Katharina ^a   Rendl, Gundula ^a   Rettenbacher, Lukas ^a   Pirich, Christian ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; LETTER; LYMPH NODE METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE; BREAST TUMOR; NOTE; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

BREAST NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79952110568     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1585-z     Document Type: Letter

References (8)

1. Berriolo-Riedinger A, Touzery C, Riedlinger JM, Toubeau M, Coudert B, Arnould L, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34(12):1915-24.
2. Duch J, Fuster D, Muñoz M, Fernández PL, Paredes P, Fontanillas M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36(10):1551-7.
3. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24(34):5366-72.
4. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27(4):535-41.
5. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92 (3):205-16.
6. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77(4):621-6.
7. Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4(2):125-31.
8. Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, et al. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009;16(12):3366-74.